Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma.

Klatte T, Ittenson A, Röhl FW, Ecke M, Allhoff EP, Böhm M.

Onkologie. 2008 Feb;31(1-2):28-34. doi: 10.1159/0000112214. Epub 2008 Jan 22.

PMID:
18268396
2.

Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.

Böhm M, Ittenson A, Klatte T, Schierbaum KF, Röhl FW, Ansorge S, Allhoff EP.

Folia Biol (Praha). 2003;49(2):63-8.

PMID:
12779014
3.

Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.

Klatte T, Ittenson A, Röhl FW, Ecke M, Allhoff EP, Böhm M.

Br J Cancer. 2006 Nov 6;95(9):1167-73. Epub 2006 Oct 10.

4.

Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.

Böhm M, Ittenson A, Schierbaum KF, Röhl FW, Ansorge S, Allhoff EP.

Eur Urol. 2002 Apr;41(4):458-67; discussion 467-8.

PMID:
12074819
5.

[Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].

Schenck M, Börgermann C, Jäger T, vom Dorp F, Sperling H, Rübben H, Lümmen G.

Urologe A. 2007 May;46(5):528-34. German.

PMID:
17356836
6.

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Wöltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN).

Br J Cancer. 2005 Mar 14;92(5):843-6.

7.

Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.

Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, Longo N, Perdonà S, Pignata S, Castello G, Scala S.

BJU Int. 2013 Sep;112(5):686-96. doi: 10.1111/bju.12068. Epub 2013 Mar 15.

9.

Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?

Hernberg M, Muhonen T, Pyrhönen S.

Ann Oncol. 1997 Jan;8(1):71-7.

PMID:
9093710
10.

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.

Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.

Br J Cancer. 2003 May 6;88(9):1346-51.

11.

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J; BEVLiN Investigators.

Ann Oncol. 2013 Sep;24(9):2396-402. doi: 10.1093/annonc/mdt228. Epub 2013 Jun 26.

PMID:
23803225
12.

Complex perioperative immuno-dysfunction in patients with renal cell carcinoma.

Böhm M, Ittenson A, Philipp C, Röhl FW, Ansorge S, Allhoff EP.

J Urol. 2001 Sep;166(3):831-6.

PMID:
11490228
13.

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L.

Ann Oncol. 2002 Nov;13(11):1799-805.

PMID:
12419754
15.

Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.

Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H, Salminen E.

Cancer. 2001 Aug 15;92(4):761-7.

PMID:
11550145
16.

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.

Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N.

J Transl Med. 2010 Aug 16;8:76. doi: 10.1186/1479-5876-8-76.

17.

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.

van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA.

Clin Cancer Res. 2007 Apr 1;13(7):2100-8. Erratum in: Clin Cancer Res. 2007 Jun 1;13(11):3433. van der Vliet, Hans J J [corrected to van der Vliet, Hans J].

18.

Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.

Göhring B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J.

Urol Res. 1996;24(5):297-303.

PMID:
8931295
19.

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.

Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM.

Cancer Res. 1992 Feb 15;52(4):851-6.

20.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

Supplemental Content

Support Center